Drug discovery uses fragment analysis to identify functional groups. By studying the fragments that make up the molecule needed to bind the target protein, researchers can better understand a molecule's pharmacological properties, such as its toxicity and side effects. RDKit fragment analysis is used to design inhibitors for the SARS-CoV-2 main protease, a COVID-19 therapeutic target . RDKit fragment analysis identified inhibitor substructures and optimised protease binding. Another study examined chemical libraries (ChEMBL, DrugCentral, PDB ligands, COCONUT, and SAVI) using fragment analysis . This signify the importance of fragments in the advancement of drug discovery has become apparent. Fragment analysis plays a crucial role in the discovery of dual-target drugs. By identifying common fragments in active molecules that bind to both targets, researchers can modify molecule structures to enhance efficacy and safety. The users can use fragment analysis to compare two datasets for each fragment type in 87 histogram plots after uploading the inhibitor sdf datafile.